BrianThomasHillMD

PubMed

• Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
  Michael D Jain, Jay Y Spiegel, Loretta J Nastoupil, John Tamaresis, Armin Ghobadi
  Journal of Clinical Oncology. 2024-10-20
• Correction: Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: classification according to the World Health Organization and International ...
  Judith A Ferry, Brian Hill, Eric D Hsi
  Journal of Hematology & Oncology. 2024-08-29
• Correction: Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
  Gaurav S Choudhary, Trinh T Tat, Saurav Misra, Brian T Hill, Mitchell R Smith
  Oncotarget. 2024-07-12

Journal Articles

• Effect of Bone Marrow CD34+Cells and T-cell Subsets on Clinical Outcomes After Myeloablative Allogeneic Hematopoietic Cell Transplantation  
  Deepa Jagadeesh, Matt Kalaycio, Brian Bolwell, Betty K Hamilton, Brian Hill, Brad Pohlman, Robert Dean, Navneet S Majhail, Sagar S Patel, Rabi Hanna, Aaron T Gerds, Ro..., Nature
• Flow Cytometric Analysis of Cerebrospinal Fluid is Low Diagnostic Yield in Samples Without Atypical Morphology or Prior History of Hematologic Malignancy  
  Collie AMB, Hill BT, Stevens GHJ, Fenner K, Gazdick E, His ED, Am J. Clin. Path., 1/1/2014
•  
  Hamilton BK, Rybicki L, Dabney J, McLellan L, Haddad H, Foster L, Abounader D, Kalaycio M, Sobecks R, Dean R, Duong H, Hill BT, Bolwell BJ, Copelan EA, Bone Marrow Transplant, 1/1/2014
• Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor alloge...  
  Hamilton BK, Rybicki L, Dean R, Majhail NS, Haddad H, Abounader D, Hanna R, Sobecks R, Duong H, Hill BT, Copelan E, Bolwell B, Kalaycio M, Am J Hematol, 1/1/2014
• Targeting mTORC1-mediated Metabolic Addiction Overcomes Fludarabine Resistance in Malignant B Cells  
  Sharma A, Janocha AJ, Hill BT, Smith MR, Erzurum SC, Almasan A, Mol Cancer Res, 1/1/2014
• Aggressive B-Cell Lymphomas With Translocations Involving BCL6 and MYC Have Distinct Clinical-Pathologic Characteristics  
  Turakhia SK, Hill BT, Dufresne SD, Nakashima MO, Cotta CV, Am J Clin Pathol, 1/1/2014
• Simultaneous Presentation of IgG4-Related Sclerosing Disease and B-cell Marginal Zone Lymphoma Successfully Treated with Chemoimmunotherapy  
  Bumma N, Cotta C, and Hill BT, Clinical Case Reports, 1/1/2014
• The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis th...  
  Bodo, J, Zhao,X, Sharma, A, Hill, BT, Portell, CA, Lannutti,BJ, Almasan, A and. His, ED, Br J Haematol, 1/1/2013
• Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL)  
  Hill BT, Caimi P, Kindwall-Keller T, Habecker B, Kalaycio M, Br J Haematol, 1/1/2013
• Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hema...  
  Hamilton BK, Bolwell B, Kalaycio M, Rybicki L, Hanna R, Sobecks R, Pohlman B, Andresen S, Dean R, Duong H, Hill, BT, Copelan E, Bone Marrow Transplant, 1/1/2013
• Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Review of the Management of Transplant-Eligible Patients  
  Lukenbill J and Hill BT, Leuk Lymphoma, 1/9/2012
• The Non-Relapse Mortality Rate for Patients with Diffuse Large B-Cell Lymphoma is Greater than Relapse Mortality Eight Years after Autologous Stem Cell Transplantation...  
  Hill, BT., Rybicki, LR., Bolwell, BJ., Smith, S., Dean, R. Kalaycio, M., Pohlman, B., Tench, S., Sobecks, R., Andresen, S., Copelan, E. Sweetenham, J, Br J Haematol, 1/1/2011
• Nonmyeloablative Second Transplants are Associated with Superior Survival and Lower Non-Relapse Mortality than Myeloablative Second Transplants  
  Hill, BT., Bolwell, BJ., Rybicki, L., Dean, R., Kalaycio, M., Pohlman, B., Tench, S., Sobecks, R., Andresen, S., and Copelan, E, Biol Blood Marrow Transplant, 1/1/2010
• Acute Myeloid Leukemia  
  Hill, BT., and Sekeres, MA, Hospital Physician, 1/1/2008
• Human N-Myristoyltransferases form stable complexes with lentiviral Nef and other viral and cellular substrate proteins  
  Hill, BT. and Skowronski, J, J. Virol., 1/1/2005
• HIV-1 Nef binds the DOCK2–ELMO1 complex to activate Rac and inhibit lymphocyte chemotaxis  
  Janardhan, AJ., Swigut, T., Hill, BT., Myers, MP. and Skowronski, J, PLOS, 1/1/2004
• Join now to see all

Books/Book Chapters

• Clinical Ophthalmic Oncology 
  Chapter: Etiology of Cancer 
  Hill, BTEditors: Singh, AD and Damato, B.Springer-Verlag, Berlin & Heidelberg, GermanyEdition 2nd,2014

Abstracts/Posters

• Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Novel Comorbidity Score Derived from a Large Multicenter Retrospective Cohort Study of Patients Treated ...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (_ 70 Years...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes and Factors Impacting Use of Axicabtagene Ciloleucel in Refractory and Relapsed Large B-Cell Lymphoma: An Intent-to-Treat Analysis
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
  Brian T. Hill, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 1 Clinical Investigation of Human Myeloid Progenitor Cells (CLT-008) As a Supportive Care Measure during Chemotherapy for Acute Myeloid Leukemia (AML)
  Wieduwilt, MJ, Cerny, J, Akard, L, Ustun, C, Ravandi, F, Rossetti, JM, Hill, BT, Brown, J , Kellerman, L, Van Syoc, R, Reed, W. Andreadis. C, ASH, 1/1/2014
• Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIRTM Protein, in Combination with Bendamustine vs Bendamustine Alone in Patients with Relapsed Chronic Lymph...
  Robak, T, Hellman, A, Kloczko, J, Loscertales, J, Lech-Maranda, E , Pagel, JM, Mato, A, Byrd,JC, Awan, FT, Hebart, H, Garcia-Marco, JA Hill, BT, Hallek, M, Stromatt,..., ASH, 1/1/2014
• Comparison of Burkitt Lymphoma (BL) and B-cell Lymphoma, Unclassifiable with Features Intermediate Between Diffuse Large B-cell Lymphoma and Burkitt Lymphoma (BCL-U) P...
  Bumma, N, Caimi, P, Rybicki, L, Jagadeesh, D, Dean RM, Pohlman, B, Smith MR, Hill BT, ASH, 1/1/2014
• Bulky Disease Does Not Adversely Affect Overall Survival in Early Stage Hodgkin Lymphoma: Role of Interim PET and Possible Omission of Radiotherapy in Select Patients
  Pophali, PA, Rybicki, L, Fenner, KB, Jagadeesh, J, Dean, RM, Pohlman, B, Smith, MR, Hill, BT, ASH, 1/1/2014
• Phase I Trial of Bortezomib and Everolimus in Relapsed/Refractory Non-Hodgkin Lymphoma
  Hill, BT, Smith, MR, Mears, J, Healy, A, Shelley, M, Wyckhouse, J, Kakish, J, Jagadeesh, D, Dean, RM Pohlman,B, Smith, SD, ASH, 1/1/2014
• Join now to see all

Lectures

• Maintenance After Frontline Therapy in Follicular Lymphoma? An Appropriate Management Plan for... 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
• Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Chronic Lymphocytic Leukemia (CLL) Transformed into Hodgkin Lymphoma (HL): Clinical Characteristics and Outcomes from a Large Multi-Center Collaboration 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase I Trial of Carfilzomib + R-CHOP (CarR-CHOP) for Frontline Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World ExperienceClinically Re... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• ASH Review 
  Cleveland, OH - 1/1/2015
• Chronic Lymphocytic Leukemia (CLL) 
  Garfield Heights, OH - 1/1/2014
• Non-Hodgkin Lymphoma 
  Lakewood, OH - 1/1/2013
• Update on Hodgkin Lymphoma 
  Cleveland, OH - 1/1/2012
• An Update in the Management of Follicular Lymphoma 
  Nashville, TN - 1/1/2011
• Chronic Leukemia 
  Cleveland, OH - 1/1/2011
• Join now to see all